Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2

Interventions

sonidegib 4HhAntag691 4gusacitinib 3IPI-926 3tazarotene 2Photochemotherapy 2Drug Evaluation 2Aminolevulinic Acid 21-phenyl-3,3-dimethyltriazene 2merphos 1Watchful Waiting 1Vincristine 1Solutions 1Sirolimus 1Red Light 1Nivolumab 1NVP-BKM120 1Microarray Analysis 1Methotrexate 1Mental Status and Dementia Tests 1Mass Spectrometry 1Ipilimumab 1Gene Expression Profiling 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Comparative Genomic Hybridization 1Carnitine 1Carboplatin 1Blue Light 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Basal Cell Nevus Syndrome × Drug Evaluation × Dermatologic × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡